Faculty

Moderators
Paul  V. Williams, MD FAAAAI
Northwest Asthma and Allergy Center

Giselle Mosnaim, MD MS FAAAAI
NorthShore University HealthSystem

Dupilumab Improves Signs And Symptoms Of Severe Atopic Dermatitis In Children Aged 6–11 Years With And Without Comorbid Allergic Rhinitis
Lisa  A. Beck, MD FAAAAI
University of Rochester

Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study
Amy McMichael, MD
Wake Forest School of Medicine

Tezepelumab Efficacy in Patients with Allergic and Non-Allergic Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
Jonathan Corren, MD
Jonathan Corren, MD, Inc.

The Effect of Benralizumab On Allergen-Induced Responses In Subjects With Mild Allergic Asthma
Gail  M. Gauvreau

Biologic Pathways Involved In Chronic Spontaneous Urticaria And Response To Benralizumab Treatment
Debajyoti Ghosh, PhD
University of Cincinnati College of Medicine

Ligelizumab is more effective in patients with chronic spontaneous urticaria previously treated with omalizumab
Karl  V. Sitz, MD FAAAAI
Little Rock Allergy and Asthma Clinic, P A

Clinical Outcomes of Biologic Therapy on Asthma in a Medically Underserved Urban Population
Sylwia Nowak, MD

A Single-Dose of REGN1908-1909 Reduced Bronchoconstriction in Cat-Allergic Subjects with Mild Asthma for up to 3 months following a controlled cat allergen challenge: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Frederic  J. De Blay De Gaix, MD
Nouvel Hopital Civil

A Comparison of Lysine Acetylsalicylate to Anti-IL4/13 and Anti-IL5 Agents in the Management of Type 2 Asthma
Meghan  E. Robbins
Pennsylvania State